Glenmark Pharmaceuticals is currently trading at Rs. 708.05, up by 10.65 points or 1.53% from its previous closing of Rs. 697.40 on the BSE.
The scrip opened at Rs. 703.00 and has touched a high and low of Rs. 710.00 and Rs. 703.00 respectively. So far 3,796 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 600.00 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 748.00 and Rs. 694.65 respectively. The current market cap of the company is Rs. 19,990.00 crore.
The promoters holding in the company stood at 46.53%, while Institutions and Non-Institutions held 38.89% and 14.58% respectively.
Glenmark Pharmaceuticals has reported a positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, in atopic dermatitis (AD), a common and serious chronic skin disease. The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in adults with moderate-to-severe AD with history of inadequate response to topical therapies.
Based on the results of this Phase 2a study, Glenmark is firmly committed to advancing GBR 830 for patients with AD and plans to initiate a Phase 2b trial in the first half of calendar year 2018. Glenmark is planning to submit these data for presentation at upcoming scientific meetings and publication in a peer-reviewed journal.
Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease, and dermatology.
